Chand Sultana Jerin, MS
Department of Immunology
Graduate school of Medicine, Nagoya University
Nagoya, Aichi, Japan.
Chand sultana Jerin secured her BSc and MS degree from the Department of Biochemistry and Molecular Biology, University of Chittagong, Bangladesh. She started her research career in June 2014 at Laboratory of Eukaryotic Gene Expression and Function, BMB, CU under the supervision of Dr. ASM Noman. During her master’s and post master’s level research, she was involved in breast cancer project to evaluate BRCA1/2 expression as a prognostic marker and identify the role of sonic hedgehog (Shh), associated with a set of immunoregulatory molecules in the TNBC subtype. Also, she was engaged in head and neck cancer project to elucidate the potential role of shh and Nrf2 as therapeutic biomarkers as well as discloses the mechanism of chemotherapeutic resistance in head and neck squamous cell carcinoma. Now, she is pursuing her PhD at department of Immunology, Nagoya University, Japan under the supervision of Dr. Nishikawa Hiroyoshi to develop a new cancer immunotherapy approaches through understanding the transcriptional and epigenetic regulation of immune inhibitory receptor PD1 in exhausted CD8+ T cells.
In her leisure time, she enjoys reading books, watching movies and traveling to new places with family and friends.
Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation. Noman ASM, Parag RR, Rashid MI, Islam S, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman L, et al., Cell Death & Disease. 2020 Aug 20;11(8):663; doi: 10.1038/s41419-020-02907-x; PMID: 3281477
Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer. Noman AS, Parag RR, Rashid MI, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman L, Shirin A, Nayeem J, et al., Therapeutic Advances in Medical Oncology. 2020 Mar 13;12:1758835920911229; doi: 10.1177/1758835920911229; PMID: 32206093